Related references
Note: Only part of the references are listed.Peptide-Based Vaccination and Induction of CD8+T-Cell Responses Against Tumor Antigens in Breast Cancer
Michiko Harao et al.
BIODRUGS (2015)
A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
Dan P. Zandberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Hideho Okada et al.
CLINICAL CANCER RESEARCH (2015)
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
Benjamin Uttenthal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
Julien Fourcade et al.
CANCER RESEARCH (2014)
Designing and building the next generation of improved vaccine adjuvants
Luis A. Brito et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Vaccination With NY- ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY- ESO-1 Antigen
Hisashi Wada et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines
Christopher B. Fox et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides
Paola Filipazzi et al.
CLINICAL CANCER RESEARCH (2012)
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2012)
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice
Ming Yang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
HLA Anchor Optimization of the Melan-A-HLA-A2 Epitope within a Long Peptide Is Required for Efficient Cross-Priming of Human Tumor-Reactive T Cells
Joe-Marc Chauvin et al.
JOURNAL OF IMMUNOLOGY (2012)
GLA-SE, a Synthetic Toll-like Receptor 4 Agonist, Enhances T-Cell Responses to Influenza Vaccine in Older Adults
Hayedeh Behzad et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Antigen delivery for cross priming via the emulsion vaccine adjuvants
Shan-Shan Shen et al.
VACCINE (2012)
Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
Juergen Kuball et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Katayoun Rezvani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents
Susanna Esposito et al.
VACCINE (2011)
Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17–18 February 2011
Marc P. Girard et al.
VACCINE (2011)
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents
J. Garcia-Sicilia et al.
VACCINE (2011)
Peptide Based Vaccine Approaches for Cancer—A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen
Paul H. Naylor et al.
Cancers (2011)
Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+T cell response in patients with metastatic esophageal squamous cell carcinoma
Makoto Iwahashi et al.
CANCER SCIENCE (2010)
Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination
Kanako Iseki et al.
CANCER SCIENCE (2010)
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial
Francois Roman et al.
VACCINE (2010)
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
Jeffrey A. Sosman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
Andreas Wack et al.
VACCINE (2008)
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
Pierre Vandepapeliere et al.
VACCINE (2008)
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity
Martijn S. Bijker et al.
JOURNAL OF IMMUNOLOGY (2007)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site
Victor Appay et al.
JOURNAL OF IMMUNOLOGY (2006)
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
RD Weeratna et al.
VACCINE (2005)
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
SA Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2005)
CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein
XP Ioannou et al.
VACCINE (2002)
Adjuvants designed for veterinary and human vaccines
J Aucouturier et al.
VACCINE (2001)
Share Paper
